Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
Enobosarm is covered by S1.2 of the effective 2026 WADA List and is prohibited in and out of competition. The S1.2 examples do not exhaust the category. [5]
S1.2; 2026 List, printed pages 5–6 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Approval and safety context
FDA states that SARMs are unapproved and warns of serious health problems. This class warning does not quantify this compound’s individual risk. [3]
- Research use and commercial availability are not evidence of safety or authorization.
Human evidence
A 12-week double-blind, placebo-controlled phase II trial enrolled 120 older men and postmenopausal women. Enobosarm increased lean body mass and improved the study’s physical-function measure at the highest tested exposure. [1]
- The original abstract was reviewed. Short-term results in this selected population do not establish durable clinical benefit, approval or long-term safety.
Product quality
A 2017 chemical survey of 44 internet products marketed as SARMs found frequent labeling discrepancies; only 23 contained a SARM. It identified ostarine, LGD-4033 or andarine among tested contents. [2]
- Selected products purchased in 2016, not current market prevalence or a certificate for any seller.
List year
The 2026 List is the effective edition on this review date. The checked 2027 S1 text showed no change, but the 2027 edition does not take effect until 1 January 2027. [5] [6] [4]
- Consult the official edition and responsible anti-doping organization for consequential decisions. This reference does not provide medical advice, a TUE decision, product certification or individual clearance.
What remains uncertain
- This is a targeted source check, not a systematic review or independent clinical/regulatory sign-off. Uncited draft claims remain unpublished.
- Chemical registry identifiers, every alias and jurisdiction-specific product availability have not been exhaustively reconciled.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 22031847
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 29183075
- FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults ↗Accessed 2026-11-10 · relevant primary-source text read
Consumer warning, approval status and reported serious risks
- 2027 Prohibited List resource page ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Resource description and effective date
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant primary-source text read
Introduction and S1, printed pages 3, 5–6
- WADA 2027 Prohibited List, currently linked English file ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Cover and S1, printed pages 1, 5–6
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.